NIH R01 · 2025
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (HISTO-FACT)
Abstract Histoplasma capsulatum causes histoplasmosis, which is estimated to occur in ~500,000 persons per year in the U.S. alone and is most common cause of HIV-related mortality in Central and South America. While many cases are asymptomatic or mildly symptomatic, disseminated histoplasmosis (particularly in those with immune compromise) leads to significant morbidity and mortality. Current therapy for moderate-severe histoplasmosis consists of induction with daily liposomal amphotericin B (3mg/kg) for 2 weeks followed by at least 12 months of itraconazole consolidation therapy. Despite these treatments, 6-month mortality remains ~25%. Further, these toxic therapies commonly cause…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.